**Supplemental file Table 6.** Length of hospital stay in total (bed days), and how many of these days were in the intensive care unit (ICU), shown as days post idarucizumab (median, IQR). Thrombotic events, n (%) and mortality, n (%) at 5, 30 and 90 days post idarucizumab are also shown.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Hospital Stay (days)** | | **Thrombosis** | | | **Mortality** | | |
| **ICU** | **Bed-days** | **0-5** | **0-30** | **0-90** | **0-5** | **0-30** | **0-90** |
| Abdominal  n=49 | 2.0 | 9.0 (4.0, 16.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (8.2) | 5 (10.2) | 7 (14.3) |
| Orthopedic  n=45 | 2.5 | 15.0 (8.0-25.0) | 2 (4.4) | 3 (6.7) | 4 (8.9) | 0 (0.0) | 3 (6.7) | 5 (11.1) |
| Vascular  n=34 | 4.0 | 9.5 (1.0,10.0) | 2 (5.9) | 3 (8.8) | 5 (14.7) | 2 (5.9) | 2 (5.9) | 3 (8.8) |
| Neurosurgery n=8 | 8.0 | 19.0 (13.5-51.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 1 (12.5) |
| Gynecology-Urology, n=4 | 0 | 4.0 (1.8, 10.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Catheter  n=29 | 5.0 | 6.5 (4.0, 17.0) | 0 (0.0) | 2 (6.9) | 2 (6.9) | 6 (20.7) | 10 (34.5) | 14 (48.3) |
| Drainage, n=20 | 7.0 | 9.0 (6.5, 20.0) | 1 (5.0) | 2 (10.0) | 2 (10.0) | 1 (5.0) | 1 (5.0) | 3 (15.0) |
| Diagnostic n=8 | 2.0 | 7.0 (3.5, 7.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 1 (12.5) | 2 (25.0) |
| No surgery n=5 | - | 5.0 (4.0, 13.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (40.0) | 2 (40.0) | 2 (40.0) |
| **Total  n=202** |  |  | **5  (2.5)** | **10 (5.0)** | **13  (6.4)** | **16  (7.9)** | **25  (12.4)** | **37  (18.3)** |

**Supplemental file Table 7.** The resumption of antithrombotic treatment in patients after their surgery or procedure (calculated as time from recorded end of procedure to time of anticoagulation initiation). \*Total includes all patients receiving some form of antithrombotic therapy, in many cases this includes more than one agent.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | UFH and/or LMWH | | VKA and all NOACs | | | ASA and/or Clopidogrel | | Total\* |
| N (%) | Hours, median (IQR) | N (%) | Days, median (IQR) | dabigatran re-initiated  N (%) | N (%) | Days median (IQR) | N (%) |
| Abdominal  n=49 | 36 (73.5) | 20  (7, 40) | 38 (77.6) | 8  (3, 15) | 35  (92.1) | 5  (10.2) | 2  (1, 5) | 44  (89.8) |
| Orthopedic  n=45 | 32 (71.1) | 36  (22, 82) | 40 (88.9) | 9  (2, 18) | 36  (90.0) | 12 (26.7) | 4 (1, 11) | 45  (100.0) |
| Vascular  n=34 | 20 (58.8) | 25  (5-52) | 25 (73.5) | 4  (2, 7) | 21  (84.0) | 9 (26.5) | 1  (1, 5) | 30  (88.2) |
| Neurosurgery n=8 | 4 (50.0) | 279  (107, 511) | 2 (25.0) | 42  (33, 51) | 1 (50.0) | 1 (12.5) | 32  (32,32) | 5  (62.5) |
| Gynecology-Urology, n=4 | 3 (75.0) | 25  (8-268) | 4 (100.0) | 11  (5-15) | 4  (100.0) | 0 | N/A | 4 (100.0) |
| Catheter  n=29 | 14 (48.3) | 56  (23, 137) | 15 (51.7) | 7  (5, 9) | 10  (66.7) | 3 (10.3) | 11  (1, 43) | 22 (75.9) |
| Drainage, n=20 | 16 (80.0) | 27  (20, 58) | 12  (60.0) | 6  (3, 9) | 10  (83.3) | 3  (15.0) | 9 (5, 67) | 19 (95.0) |
| Diagnostic n=8 | 5 (62.5) | 22  (16, 31) | 6 (75.0) | 3  (2, 4) | 5  (83.3) | 1 (12.5) | 0.2  (0.2, 0.2) | 7  (87.5) |
| No surgery n=5 | 2 (40.0) | N/A | 2 (40.0) | 12  (8-17) | 2  (100.0) | 0 | N/A | 3 (60.0) |

UFH = Unfractionated heparin, LMWH= Low-Molecular-Weight Heparin, VKA= Vitamin K antagonist, NOAC= Non vitamin K dependent oral anticoagulant, ASA=acetylsalicylic acid, IQR=Interquartile Range.